A case of chronic hepatitis C with sinus bradycardia during IFN therapy.
The patient was a 55-year-old male with no history of heart diseases. He was administered recombinant IFN alpha-2b under the diagnosis of chronic hepatitis C. Since sinus bradycardia (heart rate 40 bpm) appeared in the fourth week of administration (cumulative dose; 240 M.U), IFN was discontinued. Bradycardia was resolved 1 week after discontinuation of IFN, and the treatment was resumed with a change of the regimen to IFN-beta. Since no bradycardia was noted thereafter, IFN therapy could be completed (total dose; 108 M.U). These observations suggest that the type of IFN or total dose contributed to the appearance of cardiotoxicity.
Sasaki
M
M
Second Department of Medicine, Kurume University School of Medicine, Japan.
Sata
M
M
Suzuki
H
H
Tanikawa
K
K
D001146:Arrhythmia, Sinus / Q000139:chemically induced*; D001919:Bradycardia / Q000139:chemically induced*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins